Tiens Biotech Group (USA) Appoints New Auditing Firm

Tiens Biotech Group (USA) Appoints New Auditing Firm

October 02, 2007

    NEW YORK, Oct. 1 /Xinhua-PRNewswire/ -- Tiens Biotech
Group (USA), Inc. ("the Company" or
"Tiens"), (Amex: TBV), www.tiens-bio.com, today
announced that the audit committee of its Board of
Directors had appointed Grobstein, Horwath & Company
LLP ("GH&C") as its independent auditor
effective September 26, 2007.  GH&C replaces Moore
Stephens  Wurth Frazer & Torbet LLP
("MSWF&T") which had previously served as the
Company's audit firm of record. 

    The appointment of GH&C was made after
consideration and approval by the audit committee and  was
not the result of any disagreement between Tiens and
MSWF&T on any matter of accounting principles or
practice, financial statement disclosure, or auditing scope
or practice.

    About Grobstein, Horwath & Company LLP.

    Grobstein, Horwath & Company LLP (GH&C) was
founded in 1966. GH&C is a member firm of Horwath
International. Horwath International is among the top ten
largest accounting networks worldwide. GH&C has
extensive experience in working with companies in the
People's Republic of China which are listed in the United
States.  Also, Horwath International's extensive network
presence in Greater China, including Hong Kong, enhances
GH&C's ability to better serve its China based
clients.

    About Tiens Biotech Group (USA), Inc.
www.tiens-bio.com.

    Tiens Biotech Group (USA), Inc. (Amex: TBV) conducts
its business operations from Tianjin, People's Republic of
China. Tiens primarily engages in the research,
development, manufacturing, and marketing of nutrition
supplement products, including wellness products and
dietary nutrition supplement products, and personal care
products. 

    Tiens derives its revenues principally from product
sales to affiliated companies in China and internationally
in 63 countries.  Since its establishment, Tiens has
developed and produced 35 nutrition supplements, which
include wellness products and dietary nutrition
supplements.  Tiens develops its products at its own
product research and development center, which employs
highly qualified professionals in the fields of
pharmacology, biology, chemistry and fine chemistry. Tiens
has obtained all required certificates and approvals from
government regulatory agencies to manufacture and sell its
products in China. 

    In China, Tiens conducts the marketing and sales of its
products through its affiliated company, Tianshi
Engineering.  Tianshi Engineering markets and sells Tiens'
products in China through chain stores, domestic affiliated
companies, and its 105 branches. Outside of China, Tiens
sells its products to affiliated companies in 63 countries
who in turn sell through an extensive direct sales force,
or multi-level marketing sales force.  The Company's direct
sales marketing program is subject to governmental
regulation in each of these countries.  

    Certain statements in this press release constitute
"forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section
21E of the Securities and Exchange Act of 1934.  Such
forward-looking statements are not necessarily indicative
of future financial results, and may involve known and
unknown risks, uncertainties and other factors, which may
cause the actual results, performance or achievements of
the Company, to be materially different from any future
results, performance, or achievements expressed or implied
by such forward-looking statements. The Company's future
operating results are dependent upon many factors,
including but not limited to the Company's ability to: (i)
obtain sufficient capital or a strategic business
arrangement to fund its expansion plans; (ii) build the
management and human resources and infrastructure necessary
to support the growth of its business; (iii) competitive
factors and developments beyond the Company's control; (iv)
whether Tianshi Engineering, the Company's affiliate which
sells its products in China, obtains a direct selling
license in China; and (v) other risk factors discussed in
the Company's periodic filings with the Securities and
Exchange Commission which are available for review at
http://www.sec.gov under "Search for Company
Filings." 


    For more information, please contact:

     Investor Relations for Tiens Biotech Group (USA),
Inc.
     Tel:   [phone]
     Fax:   [phone]
     Email: [e-mail]

     Carl Hymans 
     G. S. Schwartz & Co.
     Tel:   [phone]
     Fax:   [phone]
     Email: [e-mail]